Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: The development of a risk prediction tool

Clinical Colorectal Cancer

Volumn 6, Issue 5, 2007, Pages 367-373

  Dranitsaris, George ^a   Shah, Amu ^a   Spirovski, Biljana ^a   Vincent, Mark ^a  

^a NONE

Author keywords

5 fluorouracil; Irinotecan; Oxaliplatin

Indexed keywords

BILIRUBIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ACCURACY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; COMORBIDITY; DIARRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 33847393178     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.006     Document Type: Article

References (33)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355:1041-1047.
2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
3. de Gramont A, Seymour AF, Homerin M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
4. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
5. Lyman G, Kuderer N, Crawford J, et al. Validation of a risk model for early neutropenic complications in patients receiving chemotherapy. Supp Care Cancer 2006; 14:604 (Abstract #06-041).
6. Vincent M, Dranitsaris G, Clemons M, et al. The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy. Supp Care Cancer. In press.
7. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-3205.
8. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303-2320.
9. Grem JL, Shoemaker DD, Patrelli NJ, et al. Severe life threatening toxicities observed using leucovorin with 5-fluorouracil. J Clin Oncol 1987; 5:1704-1712.
10. Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000; 5:250-259.
11. Dranitsaris G, Maroun J, Shah A. Severe chemotherapy-Induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 2005; 13:18-24.
12. Rosenoff S. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care 2004; 13:380-383.
13. Wadler S, Benson AB III, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998; 16:3169-3178.
14. Cancer Therapy Evaluation Program, National Cancer Institute. Common toxicity criteria. Version 2.0. Bethesda: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, 1999.
15. George SL. Identification and assessment of prognostic factors. Semin Oncol 1988; 15:462-471.
16. Allison PD. Logistic Regression Using the SAS System: Theory and Application. Cary, NC: SAS Institute Inc; 1999:179-216.
17. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, et al. Prognostic modeling with logistic regression analysis: in search of sensible strategies in small data sets. Med Decis Making 2001; 21:45-56.
18. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54:774-781.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
20. McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984; 4:137-150.
21. Freyer G, Rougier P, Bugat R, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. Br J Cancer 2000; 83:431-437.
22. Jansman FG, Sleijfer DT, Coenen JL, et al. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 2000; 23:255-278.
23. Cascinu S, Barni S, Labianca R, et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer 1997; 5:314-317.
24. Fortner B, Kulig K, Zhu L, et al. Patient reported symptoms of complaints associated with 5FU + irinotecan or oxaliplatin in colorectal cancer. Presented at: First Annual Chicago Supportive Oncology Conference; October 6-8, 2005; Chicago, IL. Abstract #PA-30.
25. Lyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan: role of uridine diphosphate glucuronosyltransferase isoform IAI in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
26. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:678-682.
27. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine and irinotecan. Clin Cancer Res 2005; 11:1226-1236.
28. Wasserman E, Myara A, Paumier D, et al. Baseline bilirubin and its transient early increase predicts likelihood of severe neutropenia and diarrhea in CPT-11 based chemotherapy. Proc Am Soc Clin Oncol 1997; 16:219a (Abstract #767).
29. Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:1439-1446.
30. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106:1007-1016.
31. Katz MH. Multivariable analysis: a primer for readers of the medical literature. Ann Intern Med 2003; 138:644-650.
32. Dranitsaris G, Clemons M, Verma S, et al. The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy. Lancet Oncol 2005; 6:856-863.
33. Petrella T, Joy A, Young S, et al. Identifying patients at high risk for moderate to severe nausea and vomiting following chemotherapy: the development and validation of a prediction tool for the practicing oncologist. Support Care Cancer 2006; 14:683 (Abstract #28-215).